Kaplan Fox Alerts Aardvark Therapeutics, Inc. (AARD) Investors to a Securities Class Action Deadline on October 13, 2026 Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) on behalf of investors that purchased or otherwise acquired Aardvark common stock pursuant and/or traceable to the Company's initial public offering on or about February 13, 2025, or between February 13, 2025 and May 14, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Aardvark and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 13, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
According to the complaint, the truth began to emerge on February 27, 2026 when Aardvark issued a press release "announc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial." On this news, Aardvark's stock price fell $7.02 per share, or 56.2%, to close at $5.47 per share on March 2, 2026.
Then, on May 14, 2026, according to the complaint, Aardvark issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause." On this news, Aardvark's stock price fell $2.16 per share, or 32.1%, to close at $4.57 per share on May 15, 2026.
The complaint alleges, the IPO Offering Documents and Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) ARD-101 was less safe than Defendants had led investors to believe; (ii) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/aardvark-therapeutics-inc-investor-lawsuit-learn-more-now/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309950
Source: Kaplan Fox & Kilsheimer LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Kaplan Fox & Kilsheimer LLP or all companies in the Legal industry.
Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) and Encourages Investors Who Suffered Losses to Contact the Firm
2026-08-17 1:15 PM EDT
Kaplan Fox Alerts Aardvark Therapeutics, Inc. (AARD) Investors to a Securities Class Action Deadline on October 13, 2026
2026-08-17 1:15 PM EDT
Kaplan Fox Notifies Alarum Technologies Ltd. (ALAR) Investors of a Securities Class Action Deadline on October 5, 2026
2026-08-17 1:00 PM EDT
Feb 27, 2026
An advisor enters a ticker into a brokerage dashboard. A retail investor searches a fund on Yahoo Finance. An institutional analyst checks a terminal feed before a client meeting. In that moment, they are not simply looking for a price quote. They are looking for context. And increasingly, what they see is silence. The global ETF market now exceeds $20 trillion in assets under management. At the end of November 2025, the industry included more than 15,600 products and over 30,000 ...
Litigation and Regulation
Legal